Double-Blind, Parallel Group Study to Compare the Clinical Effectiveness of Calcium Dobesilate 500 mg BID vs. Calcium Dobesilate LP 1 g OD, in Patients with Chronic Venous Insufficiency of the Lower Limbs
Background: Chronic venous insufficiency (CVI) describes a condition that affects the venous system of the lower extremities due to venous hypertension (VH. The prevalence is between 5% - 30%. CVI is associated with older age, smoking, lower extremity trauma, presence of an arteriovenous shunt, and elevated estrogen levels. All patients should be initially treated with conservative management. Venoactive drugs like calcium dobesilate are useful. Objectives: The primary objective compared the clinical improvement in patients with CVI, grades 0 - 3 of the CEAP classification of chronic venous disease, produced by two formulations of calcium dobesilate: calcium dobesilate LP 1 g OD vs calcium dobesilate 500 mg BID, immediate release. The secondary objective assessed the side effects of both formulations. Method: All patients took one tablet and one capsule at 7 am, and one capsule at 7 pm, for 8 weeks. One group received dobesilate 1 g OD and the other group received dobesilate 500 md BID. They were evaluated after 15, 30 and 60 days of treatment, using the symptom evaluation scale. Results: In both groups, there was a significant decrease in the symptom score after 15 days. Four patients in the Dobesilate OD group: had adverse effects, which did not require suspension of treatment. In the BID dobesilate group, there was one therapeutic failure, and one case of gastric discomfort. Conclusions: Prolonged-release Calcium dobesilate 1 g OD is as effective as calcium dobesilate 500 mg BID for the treatment of patients with chronic venous insufficiency.
References
[1]
Youn, Y.J. and Lee, J. (2019) Chronic Venous Insufficiency and Varicose Veins of the Lower Extremities. Korean Journal of Internal Medicine, 34, 269-283. https://doi.org/10.3904/kjim.2018.230
[2]
Schultz-Ehrenburg, U., Reich-Schupke, S., Robak-Pawelczyk, B., Rudolph, T., Moll, C., Weindorf, N., Hirche, H., Altmeyer, P. and Stücker, M. (2009) Prospective Epidemiological Study on the Beginning of Varicose Veins. Bochum Study I-IV. Phlebologie, 38, 17-25. https://doi.org/10.1055/s-0037-1622252
[3]
Evans, C.J., Fowkes, F.G., Ruckley, C.V. and Lee, A.J. (1999) Prevalence of Varicose Veins and Chronic Venous Insufficiency in Men and Women in the General Population: Edinburgh Vein Study. Journal of Epidemiology & Community Health, 53, 149-153. https://doi.org/10.1136/jech.53.3.149
[4]
Ruckley, C.V., Evans, C.J., Allan, P.L., Lee, A.J. and Fowkes, F.G. (2002) Chronic Venous Insufficiency: Clinical and Duplex Correlations. The Edinburgh Vein Study of Venous Disorders in the General Population. JournalofVascularSurgery, 36, 520-525. https://doi.org/10.1067/mva.2002.126547
[5]
Casarone, M.R., Belcaro, G., Nicolaides, A.N., Geroulakos, G., Griffin, M., Incandela, L., De Sanctis, M.T., Sabetai, M., Geroulakos, G., Agus, G., Bavera, P., Ippolito, E., Leng, G., Di Renzo, A., Cazaubon, M., Vasdekis, S., Christopoulos, D. and Veller, M. (2002) Real Epidemiology of Varicose Veins and Chronic Venous Disease: The San Valentino Vascular Screening Project. Angiology, 53, 119-130. https://doi.org/10.1177/000331970205300201
[6]
Brand, F.N., Dannenberg, A.L., Abbott, R.D. and Kannel, W.B. (1988) The Epidemiology of Varicose Veins: The Framingham Study. American Journal of Preventive Medicine, 4, 96-101. https://doi.org/10.1016/S0749-3797(18)31203-0
[7]
Callam, M.J. (1994) Epidemiology of Varicose Veins. British Journal of Surgery, 81, 167-173. https://doi.org/10.1002/bjs.1800810204
[8]
Scott, T.E., LaMorte, W.W., Gorin, D.R. and Menzoian, J.O. (1995) Risk Factors for Chronic Venous Insufficiency: A Dual Case-Control Study. Journal of Vascular Surgery, 22, 622-628. https://doi.org/10.1016/S0741-5214(95)70050-1
[9]
Jawien, A. (2003) The Influence of Environmental Factors in Chronic Venous Insufficiency. Angiology, 54, S19-S31. https://doi.org/10.1177/0003319703054001S04
Bergan, J.J., Schmid-Schonbein, G.W., Smith, P.D., Nicolaides, A.N., Boisseau, M.R. and Eklof, B. (2006) Chronic Venous Disease. New England Journal of Medicine, 355, 488-498. https://doi.org/10.1056/NEJMra055289
[12]
Lacroix, P., Aboyans, V., Preux, P.M., Houles, M.B. and Laskar, M. (2003) Epidemiology of Venous Insufficiency in an Occupational Population. International Angiology,27, 172-176.
[13]
Burnand, K.G. (2001) The Physiology and Hemodynamics of Chronic Venous Insufficiency of the Lower Limb. In: Gloviczki, P. and Yao, J.S., Eds., Handbook of Venous Disorders, 2nd Edition, Arnold, New York, 49-57.
[14]
Kahn, S.R., Comerota, A.J., Cushman, M., et al. (2014) The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies: A Scientific Statement from the American Heart Association. Circulation, 130, 1636-1661. https://doi.org/10.1161/CIR.0000000000000130
[15]
Gloviczki, P., Comerota, A.J., Dalsing, M.C., et al. (2011) The Care of Patients with Varicose Veins and Associated Chronic Venous Diseases: Clinical Practice Guidelines of the Society for Vascular Surgery and the American Venous Forum. Journal of Vascular Surgery, 53, 2S-48S. https://doi.org/10.1016/j.jvs.2011.01.079
[16]
Gschwandtner, M.E. and Ehringer, H. (2001) Microcirculation in Chronic Venous Insufficiency. Vascular Medicine, 6, 169-179. https://doi.org/10.1177/1358836X0100600308
[17]
Información Para Prescribir Doxium 500 El Salvador OM, Grünenthal de México, S.A. De C.V. Reg. Núm. 012M80, SSA IV.
[18]
Ciapponi, A., Laffaire, E. and Roqué, M. (2004) Calcium Dobesilate for Chronic Venous Insufficiency: A Systematic Review. Angiology, 55, 147-154. https://doi.org/10.1177/000331970405500206
[19]
Flota-Cervera, F., Flota-Ruiz, C., Treviño, C. and Berber, A. (2008) Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Lymphagogue Effect and Clinical Efficacy of Calcium Dobesilate in Chronic Venous Disease. Angiology, 59, 352-356. https://doi.org/10.1177/0003319707305407
[20]
Rabe, E., Jaeger, K.A., Bulitta, M. and Pannier, F. (2011) Calcium Dobesilate in Patients Suffering from Chronic Venous Insufficiency: A Double-Blind, Placebo-Controlled, Clinical Trial. Phlebology, 26, 162-168. https://doi.org/10.1258/phleb.2010.010051
[21]
Arceo, A., Berber, A. and Treviño, C. (2002) Clinical Evaluation of the Efficacy and Safety of Calcium Dobesilate in Patients with Chronic Venous Insufficiency of the Lower Limbs. Angiology, 53, 539-544. https://doi.org/10.1177/000331970205300506
[22]
Hernández, H., Eduardo, J.M., Leticia, V.G.M., Annunziato María, A., Soler María, M. and María, G.Y. (2015) Evaluación de la biodisponibilidad comparativa de un producto test conteniendo DOBESILATO de Calcio en comprimidos de 1000 mg de liberación prolongada de Laboratorios LETI, S.A.V. una dosis diaria; contra el producto de referencia DOXIUM® de Laboratorios LETI, S.A.V., conteniendo 500 mg de DOBESILATO de Calcio de liberación inmediata, administrado dos veces al día, totalizando la misma dosis de 1000 mg, en voluntarios sanos. Archivos Venezolanos de Farmacología y Terapéutica, 34, 1-3. http://ve.scielo.org/scielo.php?script=sci_arttext&pid=s0798-02642015000100001&lng=es.
[23]
Porter, J.M. and Moneta, G.L. (1995) Reporting Standards in Venous Disease: An Update. Journal of Vascular Surgery, 21, 635-645. https://doi.org/10.1016/S0741-5214(95)70195-8
[24]
Abenhaim, L., Clement, D. and Norgren, L. (1999) The Management of Chronic Venous Disorders of the Leg: An Evidence Based Report of an International Task Force. Phlebology, 14, S1-S126.
[25]
Kurz, X., Kahn, S.R., Abenhaim, L., Clement, D., Norgren, L., Baccaglini, U., et al. (1999) Chronic Venous Disorders of the Leg: Epidemiology, Outcomes, Diagnosis and Management. Summary of an Evidence-Based Report of the VEINES Task Force. Venous Insufficiency Epidemiologic and Economic Studies. International Angiology, 18, 83-102.
[26]
Leu, A.J., Leu, H.J., Franzeck, U.K. and Bollinger, A. (1995) Microvascular Changes in Chronic Venous Insufficiency—A Review. Cardiovascular Surgery, 3, 237-245. https://doi.org/10.1016/0967-2109(95)93871-L
[27]
Shami, S.K., Cheatle, T.R., Chittenden, S.J., Scurr, J.H. and Coleridge Smith, P.D. (1993) Hyperaemic Response in the Skin Microcirculation of Patients with Chronic Venous Insufficiency. British Journal of Surgery,80, 433-435. https://doi.org/10.1002/bjs.1800800408
[28]
Fagrell, B. (1979) Local Microcirculation in Chronic Venous Incompetence and Leg Ulcers. Vascular and Endovascular Surgery, 13, 217-225. https://doi.org/10.1177/153857447901300401
[29]
Fagrell, B. (1982) Microcirculatory Disturbances—The Final Cause for Venous Leg Ulcers? VASA. Zeitschrift fur Gefasskrankheiten,11, 101-103.
[30]
Hachen, H.J. and Lorenz, P. (1982) Double-Blind Clinical and Plethysmographic Study of Calcium Dobesilate in Patients with Peripheral Microvascular Disorders. Angiology, 33, 480-488. https://doi.org/10.1177/000331978203300708
[31]
Rabe, E., Ballarini, S. and Lehr, L. (2016) A Randomized, Double Blind, Placebo-Controlled, Clinical Study on the Efficacy and Safety of Calcium Dobesilate in the Treatment of Chronic Venous Insufficiency. Phlebology, 31, 264-274. https://doi.org/10.1177/0268355515586097
[32]
Widmer, L., Biland, L. and Barras, J.P. (1990) Doxium 500 in Chronic Venous Insufficiency: A Double-Blind Placebo-Controlled Multicentre Study. International Angiology, 9, 105-110.
[33]
Marinello 2002: Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo sobre la efectividad del dobesilato de calcio en el tratamiento de la hipertensión venosa en pacientes afectos de insuficiencia venosa crónica de extremidades inferiores. ESCLIN-004/99 (Quoted by Ciapponi 2004 in ref 180 above).
[34]
Casley-Smith, J.R. (1988) A Double-Blind Trial of Calcium Dobesilate in Chronic Venous Insufficiency. Angiology, 39, 853-857. https://doi.org/10.1177/000331978803901001
[35]
Flora, L.F. (1999) Estudio clínico prospectivo aleatorizado doble ciego, con control placebo, para evaluar la eficacia en la resolución del edema de origen linfático, del dobesilato de calcio en pacientes con enfermedad varicosa. No de Proyec. Knoll-mex-02-99. No de Proyec. 003/MEX/99, 184.
[36]
Dilla, T., Valladares, A., Lizán, L. and Sacristán, J.A. (2009) Adherencia y persistencia terapéutica: Causas, consecuencias y estrategias de mejora. Atención Primaria, 41, 342-348. https://doi.org/10.1016/j.aprim.2008.09.031
[37]
Lam, W.Y. and Fresco, P. (2015) Medication Adherence Measures: An Overview. BioMed Research International, 2015, Article ID: 217047. https://doi.org/10.1155/2015/217047
[38]
McQuaid, E.L. and Landier, W. (2018) Cultural Issues in Medication Adherence: Disparities and Directions. Journal of General Internal Medicine, 33, 200-206. https://doi.org/10.1007/s11606-017-4199-3
[39]
Llorca, C.V.Y., Cortés Castell, E., Ribera Casado, J.M., De Lucas Ramos, P., Casteig Ayestarán, J.L., Casteig Blanco, A., Gil Guillén, V.F. and Rizo Baeza, M. (2021) Factors Associated with Non-Adherence to Drugs in Patients with Chronic Diseases Who Go to Pharmacies in Spain. International Journal of Environmental Research and Public Health, 18, Article 4308. https://doi.org/10.3390/ijerph18084308
[40]
Ortega Cerda, J.J., Sanchez Herrera, D., Rodriguez Miranda, Ó.A. and Ortega Legaspi, J.M. (2018) Adherencia terapéutica: Un problema de atención médica. Acta médica Grupo Ángeles, 16, 226-232. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870-72032018000300226&lng=es&nrm=iso
